Doxapram HCl - CAS 7081-53-0
Catalog number:
B0084-097383
Category:
Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
C24H30N2O2·HCl·H2O
Molecular Weight:
432.98
COA:
Inquire
Targets:
Potassium Channel
Description:
Doxapram HCl inhibits TASK-1, TASK-3, TASK-1/TASK-3 heterodimeric channel function with EC50 of 410 nM, 37 μM, 9 μM, respectively.
Ordering Information
Catalog Number Size Price Stock Quantity
B0084-097383 200 mg $169 In stock
Bulk Inquiry
Publictions citing BOC Sciences Products
  • >> More
Purity:
>98%
Synonyms:
BRD-6125
MSDS:
Inquire
1.New role for FDA-approved drugs in combating antibiotic-resistant bacteria.
Andersson JA1, Fitts EC2, Kirtley ML2, Ponnusamy D2, Peniche AG3, Dann SM4, Motin VL5, Chauhan S1, Rosenzweig JA6, Sha J7, Chopra AK8. Antimicrob Agents Chemother. 2016 Apr 11. pii: AAC.00326-16. [Epub ahead of print]
Antibiotic resistance in medically relevant bacterial pathogens, coupled with a paucity of novel anti-microbial discoveries, represents a pressing global crisis. Traditional drug discovery is an inefficient and costly process; however, systematic screening of Food and Drug Administration (FDA)-approved therapeutics for other indications in humans offers a rapid alternative approach. In this study, we screened a library of 780 FDA-approved drugs to identify molecules that rendered RAW 264.7 murine macrophages resistant to cytotoxicity induced by the highly virulentYersinia pestisCO92 strain. Of these compounds, we identified 94, not classified as antibiotics, as being effective in preventingY. pestis-induced cytotoxicity. A total of 17 "down-selected" drugs, based on efficacy inin vitroscreens, were chosen for further evaluation in a murine model of pneumonic plague to delineate ifin vitroefficacy could be translatedin vivo Three drugs, doxapram (DXP), amoxapine (AXPN), and trifluoperazine (TFP), increased animal survivability despite not exhibiting any direct bacteriostatic or bactericidal effect onY.
2.Observational Study on Less Invasive Surfactant Administration (LISA) in Preterm Infants<29 Weeks - Short and Long-term Outcomes.
Teig N1, Weitkämper A1, Rothermel J1, Bigge N1, Lilienthal E1, Rossler L1, Hamelmann E1. Z Geburtshilfe Neonatol. 2015 Dec;219(6):266-273. Epub 2015 Nov 9.
Background: A recent trial has demonstrated short-term benefits of a new minimal invasive procedure of surfactant administration in spontaneously breathing preterm infants ≥26 weeks (less invasive surfactant administration, LISA). Aim: To assess safety as well as short- and long-term outcomes of the LISA procedure in preterm infants between 23-28 weeks of gestation. Study design: Preterm infants born between 23+0 and 28+6 weeks gestational age during 2 periods, 18 months before (Period 1, n=44) and 18 months after introduction of LISA (Period 2, n=53), were analyzed for neonatal outcomes. 52% of discharged infants were assessed for neurodevelopmental outcome at corrected age of 3 years. Results: In Period 2, 66% of the preterm infants needing surfactant were treated by the new method of LISA. In this period, fewer patient had to be ventilated during the first 3 days of life (42 vs. 77%, p<0.0005) and overall (55 vs. 77%, p=0.02). The median duration of mechanical ventilation was 2 vs.
3.An Impedance-Based Model for the Assessment of Cardiopulmonary Function in Rabbits.
Horsmon MS1, Vincelli NM2, Taylor JT2, Kristovich RL3. J Am Assoc Lab Anim Sci. 2016;55(2):213-20.
Improving the quality of physiologic data collected from research animals is most easily accomplished by collecting as much information as possible from a single subject, thereby reducing animal use and error associated with satellite groups. We investigated the feasibility of using a large-animal implantable telemetry device in New Zealand white rabbits (n = 6). The first task was to develop an implantation technique that yielded calibrated tidal volume (Vt) measurements that were within 10% of those obtained simultaneously from a pneumotachograph, a low-noise electrocardiogram, and stable blood pressure. The second task was to challenge implanted rabbits with the respiratory stimulant doxapram to assess linearity of the calibration across a range of Vt. Of the 3 electrode placements attempted, only one resulted in calibrations consistently below 10% error. Optimal electrode placement resulted in calibrated Vt measurements within 1.7% ± 0.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Potassium Channel Products


CAS 64-77-7 Tolbutamide

Tolbutamide
(CAS: 64-77-7)

Tolbutamide is an inhibitor of potassium channel, used for type II diabetes.

CAS 7081-53-0 Doxapram HCl

Doxapram HCl
(CAS: 7081-53-0)

Doxapram HCl inhibits TASK-1, TASK-3, TASK-1/TASK-3 heterodimeric channel function with EC50 of 410 nM, 37 μM, 9 μM, respectively.

CAS 207844-01-7 Mitiglinide calcium hydrate

Mitiglinide calcium hydrate
(CAS: 207844-01-7)

Mitiglinide calcium hydrate, a derivative of benzylsuccinic acid, is a highly selective KATP channel antagonist.

CAS 1260141-27-2 TAK438

TAK438
(CAS: 1260141-27-2)

TAK-438 is a novel P-CAB (potassium-competitive acid blocker) that reversibly inhibits H+/K+, ATPase with IC50 of 19 nM (pH 6.5), controls gastric acid secretio...

CAS 489402-47-3 ML213

ML213
(CAS: 489402-47-3)

ML213 is a selective activator of KCNQ2 (Kv7.2) and KCNQ4 (Kv7.4) with > 80-fold selectivity against other related K+ channels, and enhances Kv7.2 and Kv7.4 cha...

CAS 448895-37-2 NS 1643

NS 1643
(CAS: 448895-37-2)

NS 1643 is human ether-a-go-go related gene (hERG) KV11.1 channel activator (EC50 = 10.5 μM)

CAS 149908-53-2 Azimilide

Azimilide
(CAS: 149908-53-2)

Azimilide, also called as Stedicor, a chlorophentlturany compound, inhibits I(Ks) and I(Kr) in guinea-pig cardiac myocytes and I(Ks) (minK) channels. Phase III

BMS-919373
(CAS: 1272353-82-8)

This active molecular is a Kv1.5 potassium channel inhibitor originated by Bristol-Myers Squibb. Treatment for paroxysmal atrial fibrillation is in Phase II cli...

CAS 220641-11-2 Naminidil

Naminidil
(CAS: 220641-11-2)

Naminidil is an ATP-Sensitive Potassium Channel Vasodilator used for the treatment of Alopecia.

ML277
(CAS: 1401242-74-7)

ML277, a sulfonylpiperidine compound, has been found to be a KCNQ1 K+ channel activator and could be used in the study of the activity of K+ channel in human ca...

MK-7145
(CAS: 1255204-84-2)

This active molecular is a selective renal outer medullary potassium channel (RMOK) inhibitor originated by Merck Sharp & Dohme for the treatment of hypertensio...

CAS 38304-91-5 Minoxidil

Minoxidil
(CAS: 38304-91-5)

Minoxidil is a vasodilator medication known for its ability to slow or stop hair loss and promote hair regrowth.

CAS 582323-16-8 ICA-069673

ICA-069673
(CAS: 582323-16-8)

ICA-069673 is an orally active, potent and selective KCNQ2/Q3 potassium channel activator (IC50= 0.69 μM) with 20-fold selectivity for KV7.2/KV7.3 over KV7.3/KV...

CAS 433937-93-0 AZD-0837

AZD-0837
(CAS: 433937-93-0)

AZD0837 is an oral direct thrombin inhibitor currently in clinical development for the prevention of stroke and systemic embolic events in patients with atrial ...

CAS 75507-68-5 Flupirtine maleate

Flupirtine maleate
(CAS: 75507-68-5)

Flupirtine maleate is the salt form of Flupirtine, which is a centrally acting non-opioid analgesia, is a selective neuronal potassium channel opener that also ...

CAS 33400-45-2 Flupirtine Hydrochloride

Flupirtine Hydrochloride
(CAS: 33400-45-2)

Flupirtine is an agonist of Kv7 potassium (KCNQ) channels, doubles channel currents when applied at 10 µM.

Way 123398
(CAS: 138490-53-6)

Way 123398 is a class III antiarrhythmic agent. It is a Potassium channel antagonist originated by Wyeth. No preclinical development for Arrhythmias in USA was ...

CAS 113559-13-0 E-4031

E-4031
(CAS: 113559-13-0)

E-4031, a benzenesulfonamide derivative, could be used as a Class III antiarrhythmic agent due to its effect of blocking the ERG potassium channels.

CAS 152802-84-1 KRN4884

KRN4884
(CAS: 152802-84-1)

KRN4884, a synthesized 3-pyridine derivative, shows a long-lasting antihypertensive effect based on its potent potassium channel-opening action. The long-lastin...

CAS 134017-78-0 U89232

U89232
(CAS: 134017-78-0)

U89232, a cardioselective cyanoguanidine analog of cromakalim, appears to be a cardioselective KATP channel opener.

Chemical Structure

CAS 7081-53-0 Doxapram HCl

Quick Inquiry

Verification code

Featured Items